Xencor, Inc. is a US-based pharmaceutical company specializing in developing engineered monoclonal antibody treatments for severe diseases. With a Risk Rating Score of 23.6, it is categorized as a medium-risk company. Using its XmAb technology platform, Xencor creates antibody product candidates like XmAb5871 and XmAb7195, with several pre-clinical stage candidates in its portfolio. The company generates revenue through research collaborations and licensing its internally developed drug candidates.